Tinlarebant NDA submission completed for Stargardt disease type 1

Belite Bio has completed its New Drug Application submission to the FDA for tinlarebant, an investigational oral treatment being developed for Stargardt disease type 1.

The application was submitted through the FDA’s rolling review process and follows Breakthrough Therapy Designation for tinlarebant in this indication. The FDA will now decide whether to accept the application for review; if accepted, a target date for a regulatory decision will be set under the Prescription Drug User Fee Act.^1

Don’t miss out on hearing about our latest peer-reviewed articles, expert opinions, conference news, podcasts and more.

Register Register

Stargardt disease type 1 is a rare inherited retinal disease caused by biallelic mutations in the ABCA4 gene. It is associated with progressive macular degeneration and central vision loss, often beginning in childhood or early adulthood. No treatment is currently approved for the condition, leaving an important unmet need for therapies that may slow disease progression.^1,2

Tinlarebant is designed to reduce the build-up of vitamin A-derived toxic by-products in the retina. It works by lowering serum retinol binding protein 4, which is involved in transporting retinol from the liver to the eye. By reducing retinol delivery to the retina, the therapy aims to limit bisretinoid accumulation, a process implicated in retinal degeneration in Stargardt disease type 1.¹

Clinical trial data

The NDA is supported by topline data from DRAGON, a 24-month, randomized, double-masked, placebo-controlled, global phase 3 trial in 104 adolescents with Stargardt disease type 1.³ Patients were randomized 2:1 to tinlarebant or placebo.

Tinlarebant met the primary endpoint, reducing study-eye retinal lesion growth by 35.7% versus placebo, as measured by definitely decreased autofluorescence on fundus autofluorescence imaging (p=0.0033). Treatment effects were also reported in the fellow eye and on the key secondary endpoint of decreased autofluorescence lesion growth.

The 5 mg daily dose reduced retinol binding protein 4 levels by approximately 80% from baseline. Visual acuity changed minimally over 24 months in both treatment groups, which Belite Bio stated was consistent with natural history data. Tinlarebant was generally well tolerated, with four treatment-related discontinuations and no discontinuations due to non-ocular adverse events.²

For ophthalmologists, the regulatory milestone is notable because Stargardt disease type 1 remains a progressive condition without an approved treatment. However, tinlarebant remains investigational, and the clinical relevance of the DRAGON findings will depend on the full data package, FDA review outcome, and longer-term evidence on visual function and disease progression.

Clinical takeaway

The completed NDA submission moves tinlarebant closer to potential FDA review for Stargardt disease type 1. If approved, it could represent an important new option in an area of high unmet need, but its place in clinical practice will depend on regulatory assessment and the extent to which structural benefits translate into meaningful outcomes for patients.

References

1. Belite Bio. Belite Bio completes rolling submission of New Drug Application to U.S. Food and Drug Administration for tinlarebant for the treatment of Stargardt disease type 1 [Press release]. June 12, 2026. Available at: www.globenewswire.com/news-release/2026/06/13/3311366/0/en/belite-bio-completes-rolling-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-tinlarebant-for-the-treatment-of-stargardt-disease-type-1.html (accessed June 19, 2026).
2. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101:25–30
3. Belite Bio. New hope for people living with a disease once deemed untreatable: Belite Bio announces positive topline results from the pivotal global, phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease [Press release]. December 1, 2025. Available at: www.investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite (accessed June 19, 2026).